Welcome!

News Feed Item

Aeolus Announces First Quarter Fiscal Year 2014 Financial Results

MISSION VIEJO, CA -- (Marketwired) -- 02/14/14 -- Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with significant funding from the US Government, announced today financial results for the three months ended December 31, 2013.

The Company reported a net loss of approximately $695,000, or $0.01 per share for the three months ended December 31, 2013. This compares to a net profit of $4,028,000, or $0.03 per share, which includes a non-cash adjustment of approximately $4,510,000 related to decreases in the fair value of warrants that are included as a component of other income (expenses) in the statement of operations, for the three months ended December 31, 2012.

"During the quarter, we announced positive data from studies demonstrating that AEOL 10150 significantly improves survival and protects lungs in mice exposed to lethal radiation. This data builds on the growing body of positive data that we hope will form the basis of a pre-Emergency Use Authorization application later this year," stated John L. McManus, President and Chief Executive Officer. "We also filed a new provisional patent application that, if granted, would substantially increase the life of the patent protection surrounding AEOL 10150. Work under the contract is expected to accelerate during the second quarter as we expect to initiate up to 6 murine efficacy studies, continue a large non-human primate efficacy study, finalize process development and validation of our drug substance and prepare our IND filing for lung acute radiation syndrome."

Revenue for the three months ended December 31, 2013 was approximately $793,000, which compares to revenue of $1,342,000 for the three months ended December 31, 2012. The revenue is from the contract with BARDA announced on February 11, 2011. Lower revenue in 2013 reflects both the timing of the initiation of program items as well as revenue recognition under accounting rules.

Research and development expenses decreased to approximately $707,000 for the three months ended December 31, 2013, from approximately $1,169,000 for the three months ended December 31, 2012. The decrease in 2013 expenses reflects both the timing of the initiation of program items under the BARDA contract as well as expense recognition under accounting rules.

General and administrative expenses were approximately $781,000 for the three months ended December 31, 2013 compared to approximately $655,000 for the three months ended December 31, 2012. The higher expense was primarily due to stock option expense.

Key accomplishments during the quarter include:

  • Announced data from BARDA-funded studies demonstrating AEOL-10150 increased survival at 180 days from 10% to 40% in mice receiving lethal irradiation
  • Filed a provisional patent application covering novel synthesis routes, crystal forms and pharmaceutical compositions of AEOL 10150 and related porphyrin compounds

As of December 31, 2013, the Company had approximately $534,000 in cash and cash equivalents and 134,550,068 common shares outstanding. The Company had accounts receivable of $1,111,000 and accounts payable of $1,395,000 on December 31, 2013. Aeolus has filed today with the SEC its Quarterly Report on Form 10-Q for the quarter ended December 31, 2013. Aeolus urges its investors to read this quarterly filing as well as its Annual Report on Form 10-K, also filed with the SEC, for further details concerning the Company. The Quarterly Report on Form 10-Q and the Annual Report on Form 10-K are also available on the Company's website, at http://www.aeoluspharma.com.

About AEOL 10150
AEOL 10150 is a broad-spectrum catalytic antioxidant specifically designed to neutralize reactive oxygen and nitrogen species. The neutralization of these species reduces oxidative stress, inflammation, and subsequent tissue damage-signaling cascades resulting from radiation exposure. AEOL 10150 may have a profound beneficial impact on people who have been exposed, or are about to be exposed, to high-doses of radiation in the treatment of oncology.

AEOL 10150 has performed well in preclinical and non-clinical studies, demonstrating statistically significant survival efficacy in an acute radiation-induced lung injury model, and was well-tolerated in two human clinical trials. The Company believes it could have a profound beneficial impact on people who have been exposed, or are about to be exposed, to high-doses of radiation, whether from cancer therapy or a nuclear event.

About Aeolus Pharmaceuticals
Aeolus Pharmaceuticals is developing a platform of a new class of broad-spectrum, catalytic-antioxidant compounds that protect healthy tissue from the damaging effects of radiation. Its first compound, AEOL 10150, is being developed, with funding by the US Department of Health and Human Services, as a medical countermeasure against chemical and radiological weapons, where its initial target indications are as a protective agent against the effects of acute radiation syndrome and delayed effects of acute radiation exposure. Aeolus' strategy is to leverage the substantial investment in toxicology, manufacturing, and preclinical and clinical studies made by US Government agencies in AEOL 10150, including the contract with BARDA valued, with options, at up to $118.4 million, to efficiently develop the compound for use in oncology. For more information, please visit Aeolus's corporate website at www.aeoluspharma.com.

Forward-Looking Statements

The statements in this press release that are not purely statements of historical fact are forward-looking statements. Such statements include, but are not limited to, those relating to Aeolus' product candidates, as well as its proprietary technologies and research programs, the Company's potential initiation of large efficacy studies in mice and NHPs, as well as a phase 1 study in healthy normal volunteers, the BARDA Contract, and the expected use of proceeds from the financing. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Aeolus' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Important factors that could cause results to differ include risks associated with uncertainties of progress and timing of clinical trials, scientific research and product development activities, difficulties or delays in development, testing, obtaining regulatory approval, the need to obtain funding for pre-clinical and clinical trials and operations, the scope and validity of intellectual property protection for Aeolus' product candidates, proprietary technologies and their uses, and competition from other biopharmaceutical companies, and whether BARDA exercises one or more additional options under the BARDA Contract. Certain of these factors and others are more fully described in Aeolus' filings with the Securities and Exchange Commission, including, but not limited to, Aeolus' Annual Report on Form 10-K for the year ended September 30, 2013. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

                        AEOLUS PHARMACEUTICALS, INC.
                   CONDENSED CONSOLIDATED BALANCE SHEETS
                                 (Unaudited)
                    (In thousands, except per share data)

                                                December 31,  September 30,
                                                    2013           2013
                                               -------------  -------------
                    ASSETS
Current assets:
  Cash and cash equivalents                    $         534  $         869
  Accounts receivable                                  1,111            370
  Deferred subcontractor cost                          1,043            656
  Prepaids and other current assets                       38             39
                                               -------------  -------------
    Total current assets                               2,726          1,935

Investment in CPEC LLC                                    32             32
                                               -------------  -------------
    Total assets                               $       2,758  $       1,966
                                               =============  =============

     LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
  Accounts payable and accrued expenses        $       1,395  $         579
  Deferred revenue                                     1,085            682
                                               -------------  -------------
    Total current liabilities                          2,480          1,261

    Total liabilities                                  2,480          1,261
                                               -------------  -------------

Commitments and contingencies (Note F)

Stockholders' equity:
  Preferred stock, $.01 par value per share,
   10,000,000 shares authorized:
  Series A nonredeemable convertible preferred
   stock, 1,250,000 shares authorized as of
   December 31, 2013 and September 30, 2013,
   respectively; no shares issued and
   outstanding as of December 31, 2013 and
   September 30, 2013, respectively                       --             --
  Series B nonredeemable convertible preferred
   stock, 1,600,000 shares authorized as of
   December 31, 2013 and September 30, 2013,
   respectively; 526,080 shares issued and
   outstanding as of December 31, 2013 and
   September 30, 2013, respectively                        5              5
  Common stock, $.01 par value per share,
   200,000,000 shares authorized; 134,550,068
   shares issued and outstanding as of
   December 31, 2013 and September 30, 2013,
   respectively                                        1,346          1,346
  Additional paid-in capital                         183,544        183,276
  Accumulated deficit                               (184,617)      (183,922)
                                               -------------  -------------
    Total stockholders' equity                           278            705
                                               -------------  -------------
    Total liabilities and stockholders' equity $       2,758  $       1,966
                                               =============  =============

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.


                        AEOLUS PHARMACEUTICALS, INC.
               CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                                 (Unaudited)
                    (In thousands, except per share data)

                                                     Three Months Ended
                                                        December 31,
                                                 --------------------------
                                                     2013          2012
                                                 ------------  ------------
Revenue:
  Contract revenue                               $        793  $      1,342

Costs and expenses:
  Research and development                                707         1,169
  General and administrative                              781           655
                                                 ------------  ------------
    Total costs and expenses                            1,488         1,824
                                                 ------------  ------------
Loss from operations                                     (695)         (482)

Non-cash financing charges and change in fair
 value of warrants                                         --         4,510
                                                 ------------  ------------
Net (loss) income                                $       (695) $      4,028
                                                 ============  ============

Net (loss) income per weighted share
 attributable to common stockholders:
  Basic                                          $       (695) $      2,049
                                                 ------------  ------------
  Diluted                                        $       (695) $       (200)
                                                 ============  ============

  Basic net (loss) income per common share       $      (0.01) $       0.03
                                                 ------------  ------------
  Diluted net (loss) income per common share     $      (0.01) $       0.00
                                                 ============  ============

Weighted average common shares outstanding:
  Basic                                               134,550        62,732
                                                 ------------  ------------
  Diluted                                             134,550        65,635
                                                 ============  ============

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.


                        AEOLUS PHARMACEUTICALS, INC.
               CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                                 (Unaudited)
                                (In thousands)

                                                     Three Months Ended
                                                        December 31,
                                                 --------------------------
                                                     2013          2012
                                                 ------------  ------------
Cash flows from operating activities:
  Net (loss) income                              $       (695) $      4,028
  Adjustments to reconcile net (loss) income to
   net cash used in operating activities:
    Stock-based compensation                              268            72
    Change in fair value of warrants                       --        (4,510)
    Change in assets and liabilities:
      Accounts receivable                                (741)         (668)
      Deferred subcontractor cost                        (387)           --
      Prepaid and other assets                              1             7
      Accounts payable and accrued expenses               816           792
      Deferred revenue                                    403            --
                                                 ------------  ------------
Net cash used in operating activities                    (335)         (279)
                                                 ------------  ------------
Net decrease in cash and cash equivalents                (335)         (279)
Cash and cash equivalents at beginning of period          869           281
                                                 ------------  ------------
Cash and cash equivalents at end of period       $        534  $          2
                                                 ============  ============

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact:
John McManus
President and Chief Executive Officer
Aeolus Pharmaceuticals, Inc.
1-(949) 481-9825

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
As Marc Andreessen says software is eating the world. Everything is rapidly moving toward being software-defined – from our phones and cars through our washing machines to the datacenter. However, there are larger challenges when implementing software defined on a larger scale - when building software defined infrastructure. In his session at 16th Cloud Expo, Boyan Ivanov, CEO of StorPool, provided some practical insights on what, how and why when implementing "software-defined" in the datacent...
Blockchain. A day doesn’t seem to go by without seeing articles and discussions about the technology. According to PwC executive Seamus Cushley, approximately $1.4B has been invested in blockchain just last year. In Gartner’s recent hype cycle for emerging technologies, blockchain is approaching the peak. It is considered by Gartner as one of the ‘Key platform-enabling technologies to track.’ While there is a lot of ‘hype vs reality’ discussions going on, there is no arguing that blockchain is b...
Blockchain is a shared, secure record of exchange that establishes trust, accountability and transparency across business networks. Supported by the Linux Foundation's open source, open-standards based Hyperledger Project, Blockchain has the potential to improve regulatory compliance, reduce cost as well as advance trade. Are you curious about how Blockchain is built for business? In her session at 21st Cloud Expo, René Bostic, Technical VP of the IBM Cloud Unit in North America, discussed the b...
ChatOps is an emerging topic that has led to the wide availability of integrations between group chat and various other tools/platforms. Currently, HipChat is an extremely powerful collaboration platform due to the various ChatOps integrations that are available. However, DevOps automation can involve orchestration and complex workflows. In his session at @DevOpsSummit at 20th Cloud Expo, Himanshu Chhetri, CTO at Addteq, will cover practical examples and use cases such as self-provisioning infra...
"Storpool does only block-level storage so we do one thing extremely well. The growth in data is what drives the move to software-defined technologies in general and software-defined storage," explained Boyan Ivanov, CEO and co-founder at StorPool, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.
Is advanced scheduling in Kubernetes achievable?Yes, however, how do you properly accommodate every real-life scenario that a Kubernetes user might encounter? How do you leverage advanced scheduling techniques to shape and describe each scenario in easy-to-use rules and configurations? In his session at @DevOpsSummit at 21st Cloud Expo, Oleg Chunikhin, CTO at Kublr, answered these questions and demonstrated techniques for implementing advanced scheduling. For example, using spot instances and co...
A strange thing is happening along the way to the Internet of Things, namely far too many devices to work with and manage. It has become clear that we'll need much higher efficiency user experiences that can allow us to more easily and scalably work with the thousands of devices that will soon be in each of our lives. Enter the conversational interface revolution, combining bots we can literally talk with, gesture to, and even direct with our thoughts, with embedded artificial intelligence, whic...
The use of containers by developers -- and now increasingly IT operators -- has grown from infatuation to deep and abiding love. But as with any long-term affair, the honeymoon soon leads to needing to live well together ... and maybe even getting some relationship help along the way. And so it goes with container orchestration and automation solutions, which are rapidly emerging as the means to maintain the bliss between rapid container adoption and broad container use among multiple cloud host...
The cloud era has reached the stage where it is no longer a question of whether a company should migrate, but when. Enterprises have embraced the outsourcing of where their various applications are stored and who manages them, saving significant investment along the way. Plus, the cloud has become a defining competitive edge. Companies that fail to successfully adapt risk failure. The media, of course, continues to extol the virtues of the cloud, including how easy it is to get there. Migrating...
Imagine if you will, a retail floor so densely packed with sensors that they can pick up the movements of insects scurrying across a store aisle. Or a component of a piece of factory equipment so well-instrumented that its digital twin provides resolution down to the micrometer.
The need for greater agility and scalability necessitated the digital transformation in the form of following equation: monolithic to microservices to serverless architecture (FaaS). To keep up with the cut-throat competition, the organisations need to update their technology stack to make software development their differentiating factor. Thus microservices architecture emerged as a potential method to provide development teams with greater flexibility and other advantages, such as the abili...
In his keynote at 18th Cloud Expo, Andrew Keys, Co-Founder of ConsenSys Enterprise, provided an overview of the evolution of the Internet and the Database and the future of their combination – the Blockchain. Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life settle...
Product connectivity goes hand and hand these days with increased use of personal data. New IoT devices are becoming more personalized than ever before. In his session at 22nd Cloud Expo | DXWorld Expo, Nicolas Fierro, CEO of MIMIR Blockchain Solutions, will discuss how in order to protect your data and privacy, IoT applications need to embrace Blockchain technology for a new level of product security never before seen - or needed.
As DevOps methodologies expand their reach across the enterprise, organizations face the daunting challenge of adapting related cloud strategies to ensure optimal alignment, from managing complexity to ensuring proper governance. How can culture, automation, legacy apps and even budget be reexamined to enable this ongoing shift within the modern software factory? In her Day 2 Keynote at @DevOpsSummit at 21st Cloud Expo, Aruna Ravichandran, VP, DevOps Solutions Marketing, CA Technologies, was jo...